Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.

Abstract

Splenectomy remains the preferred treatment for chronic immune thrombocytopenia (ITP) after corticosteroid failure, despite the risks of despite surgical complications and infection. The aim of this study was to assess the efficacy of and tolerance to rituximab through a retrospective analysis of 35 refractory/relapsing ITP patients treated from 2004 to 2013. The median age of subjects was 46years (14-80). Rituximab was given at a weekly dose of 375mg/m(2) for 4weeks. Median time from diagnosis to first infusion was 17months (1-362) and follow-up was 47months (2-133). The overall response rates at 1 and 2years after the first infusion were 47 and 38%, with complete response rates of 24 and 25%, respectively. Median duration of response was 38months (1-123), with 37% of patients maintaining a durable response (>1year). Twenty-nine percent of patients had undergone splenectomy. A durable response after rituximab was more frequently observed in patients undergoing second-line therapy than those in third or later (83 versus 35%, P=0.01). Forty-four percent of patients experienced mild hypogammaglobulinaemia after rituximab, and no clinical infection occurred. To conclude, rituximab should be considered as an alternative treatment to splenectomy. Its efficacy and safety profile should lead us to choose this medical option therapy before surgery for ITP patients.